Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on August 19, 2026 reporting Item 8.01 (Other Events). Merger shareholder vote remains scheduled for August 28, 2026; board continues unanimous recommendation for Vertex’s $85-per-share offer.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger shareholder vote remains scheduled for August 28, 2026; board continues unanimous recommendation for Vertex’s $85-per-share offer
- Litigation and demand letters allege misleading merger disclosures; supplemental proxy disclosures aim to reduce injunction risk and transaction delays
- J.P. Morgan valuation range $30.75–$95.00 per share; DCF range $68.25–$86.00 versus $85 merger consideration
- Revised forecasts show risk-adjusted revenue reaching $1,057 million in 2030 and $5,300 million in 2036
- Advisor fees total approximately $69.4 million for J.P. Morgan and $60.8 million for Leerink Partners, mostly contingent on closing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.